🇺🇸 FDA

Company profile · Sponsor

Krystal

Krystal Biotech Netherlands B.V.

KRYS · NYSE biotech PITTSBURGH, PA, EU
Pipeline
14
Drugs
1
Patents
8

Quick answer

Krystal (KRYS) is a biotech company. headquartered in PITTSBURGH, PA, EU. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker KRYS
Exchange NYSE
Company type biotech
Headquarters PITTSBURGH, PA, EU
SEC CIK 0001711279

Pipeline (14)

Search pipeline →

  1. KB803

    Krystal

    Dystrophic Epidermolysis Bullosa

    phase 3 mab active

    1 trial

  2. Open Label Topical Beremagene Geperpavec (B-VEC)

    Krystal

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    1 trial

  3. Topical Beremagene Geperpavec

    Krystal

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    2 trials

  4. KB105

    Krystal

    Autosomal Recessive Ichthyosis

    phase 2 mab active

    1 trial

  5. KB105

    Krystal

    TGM-1 Related Autosomal Recessive Congenital Ichthyosis

    phase 2 mab active

    1 trial

  6. KB304

    Krystal

    Wrinkles in Decolletage

    phase 2 mab active

    1 trial

  7. KB707

    Krystal

    Cancer

    phase 2 mab active

    1 trial

  8. KB707

    Krystal

    Lung Cancer, Non-small Cell

    phase 2 mab active

    1 trial

  9. KB801

    Krystal

    Neurotrophic Keratitis

    phase 2 mab active

    1 trial

  10. Mebendazole

    Krystal

    Pilomyxoid Astrocytoma

    phase 2 small molecule completed

    1 trial

  11. KB301

    Krystal

    Skin Roughness

    phase 1 mab active

    1 trial

  12. KB407 (Nebulization)

    Krystal

    Cystic Fibrosis

    phase 1 mab active

    2 trials

  13. KB408 (Nebulization)

    Krystal

    Alpha 1-Antitrypsin Deficiency

    phase 1 small molecule active

    1 trial

  14. LY2456302

    Krystal

    Anxiety Disorders

    phase 1 small molecule terminated

    1 trial

Drugs (1)

Search drugs →

  1. beremagene geperpavec

    VYJUVEK

    D03AX16

Patents (8)

Search patents →

  1. US 12364775

    Viral vectors for cancer therapy

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12128122

    Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11918660

    Viral vectors for cancer therapy

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11865148

    Methods of delivering transgenes to the eye

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11779660

    Viral vectors for cancer therapy

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11717547

    Compositions and methods for the treatment of autosomal recessive congenital ichthyosis

    Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11642384

    Compositions and methods for the treatment of Netherton Syndrome

    Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11185564

    Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Krystal?

Krystal (KRYS) is a biotech company. headquartered in PITTSBURGH, PA, EU. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Krystal sponsor?

We track 14 ClinicalTrials.gov-linked programs for Krystal, including KB803 and 13 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Krystal company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.